New drug aims to fight skin cancer in transplant patients
Disease control
Terminated
This study was designed to test a drug called tolododekin alfa (ANK-101) given before surgery to kidney transplant recipients with high-risk skin cancer. The goal was to see if the drug could reduce the number of cancer cells in the removed tissue. However, the trial was withdraw…
Phase: PHASE1 • Sponsor: Ankyra Therapeutics, Inc • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC